HIDEA syndrome is caused by biallelic, pathogenic, rare or founder P4HTM variants impacting the active site or the overall stability of the P4H-TM protein.


Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
11 2022
Historique:
revised: 21 07 2022
received: 02 06 2022
accepted: 24 07 2022
pubmed: 31 7 2022
medline: 7 10 2022
entrez: 30 7 2022
Statut: ppublish

Résumé

HIDEA syndrome is caused by biallelic pathogenic variants in P4HTM. The phenotype is characterized by muscular and central hypotonia, hypoventilation including obstructive and central sleep apneas, intellectual disability, dysautonomia, epilepsy, eye abnormalities, and an increased tendency to develop respiratory distress during pneumonia. Here, we report six new patients with HIDEA syndrome caused by five different biallelic P4HTM variants, including three novel variants. We describe two Finnish enriched pathogenic P4HTM variants and demonstrate that these variants are embedded within founder haplotypes. We review the clinical data from all previously published patients with HIDEA and characterize all reported P4HTM pathogenic variants associated with HIDEA in silico. All known pathogenic variants in P4HTM result in either premature stop codons, an intragenic deletion, or amino acid changes that impact the active site or the overall stability of P4H-TM protein. In all cases, normal P4H-TM enzyme function is expected to be lost or severely decreased. This report expands knowledge of the genotypic and phenotypic spectrum of the disease.

Identifiants

pubmed: 35908151
doi: 10.1111/cge.14203
doi:

Substances chimiques

Amino Acids 0
Codon, Nonsense 0
Prolyl Hydroxylases EC 1.14.11.-

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-450

Informations de copyright

© 2022 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.

Références

Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Hum Genet. 2021 Jul;140(7):1011-1029
pubmed: 33710394
Eur J Med Genet. 2014 Oct;57(10):543-51
pubmed: 25078763
Mol Cell. 2008 May 23;30(4):393-402
pubmed: 18498744
Clin Genet. 2022 Nov;102(5):444-450
pubmed: 35908151
Genet Med. 2019 Oct;21(10):2355-2363
pubmed: 30940925
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Eur J Hum Genet. 2021 Oct;29(10):1536-1541
pubmed: 34285383
Neurology. 2006 Nov 28;67(10):1769-73
pubmed: 17130408
Am J Med Genet A. 2020 Dec;182(12):2999-3006
pubmed: 32965080
Pediatr Pulmonol. 2022 Jul;57(7):1826-1829
pubmed: 35546426
J Biol Chem. 2021 Jan-Jun;296:100197
pubmed: 33334883
eNeuro. 2021 Jan 8;8(1):
pubmed: 33298456

Auteurs

Minna Kraatari-Tiri (M)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Clinical Genetics and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Leila Soikkonen (L)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Clinical Genetics and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Matti Myllykoski (M)

Department of Biomedicine, University of Bergen, Bergen, Norway.

Yalda Jamshidi (Y)

Genetics Section, Molecular and Clinical Sciences Research Institute, St. George's, University of London, London, UK.

Ehsan G Karimiani (EG)

Genetics Section, Molecular and Clinical Sciences Research Institute, St. George's, University of London, London, UK.
Department of Genetics, Next Generation Polyclinic, Mashhad, Iran.

Jonna Komulainen-Ebrahim (J)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Children and Adolescents and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Hanna Kallankari (H)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Children and Adolescents and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Cyril Mignot (C)

APHP.Sorbonne Université, Département de Génétique, Hôpital Armand Trousseau and Groupe Hospitalier Pitié-Salpêtrière, Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, France.

Christel Depienne (C)

Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière, APHP.Sorbonne Université, Paris, France.

Boris Keren (B)

Département de Génétique, Groupe Hospitalier Pitié-Salpêtrière, APHP.Sorbonne Université, Paris, France.

Marie-Christine Nougues (MC)

Département de Neuropédiatrie, APHP.Sorbonne Université, Hôpital Trousseau, Trousseau, France.

Zahra Alsahlawi (Z)

Department of Pediatrics, Salmaniya Medical Complex, Kingdom of Bahrain, Bahrain.

Antonio Romito (A)

Department of Medical Reporting and Genomics, Centogene GmbH, Rostock, Germany.

Javier Martini (J)

Department of Medical Reporting and Genomics, Centogene GmbH, Rostock, Germany.

Mehran B Toosi (MB)

Department of Pediatrics, School of medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Christopher J Carroll (CJ)

Genetics Section, Molecular and Clinical Sciences Research Institute, St. George's, University of London, London, UK.

Kornelia Tripolszki (K)

Department of Medical Reporting and Genomics, Centogene GmbH, Rostock, Germany.

Peter Bauer (P)

Department of Medical Reporting and Genomics, Centogene GmbH, Rostock, Germany.

Johanna Uusimaa (J)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Children and Adolescents and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Aida M Bertoli-Avella (AM)

Department of Medical Reporting and Genomics, Centogene GmbH, Rostock, Germany.

Peppi Koivunen (P)

Biocenter Oulu, University of Oulu, Oulu, Finland.
Faculty of Biochemistry and Molecular Medicine, Oulu Centre for Cell-Matrix Research, University of Oulu, Oulu, Finland.

Elisa Rahikkala (E)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Clinical Genetics and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH